History

Milestones / Highlights
2021
  • IND approvals of DBPR115 by US FDA and TFDA and initiation of Phase I clinical trial in Taiwan
  • IND approval of DBPR216 by US FDA and TFDA
  • Technology transfer of DBPR211 to Applied Biopharma LLC, the subsidiary of Agentix Corp in the US
  • Technology transfer of DBPR215 to Jiayi Biomedical Co., Ltd.
  • Technology transfer of DBPR114 to LaunXP Biomedical Co., Ltd.
  • Identification of DBPR168 an agent against chemotherapy-induced peripheral neuropathy as a neuroprotective drug candidate
  • Identification of DBPR728 an aurora kinase inhibitor which reduces levels of MYC oncoproteins as an anti-cancer drug candidate
  • Technology transfer of DBPR186 to Taivex Therapeutics Co.
2020
  • Technology transfer of DBPR112 to Anbogen Therapeutics
  • Identification of DBPR186 an PS-targeting drug conjugate as an anti-cancer drug candidate
  • Joined Anti-COVID-19 Drug Development Program with ATRI
2019
  • Initiation of Phase III clinical trials of DBPR108
  • Technology transfer of DBPR216 to Taivex Therapeutics Co.
  • Identification of DBPR807 an CXCR4 antagonist as a HCC/AMI/PBSCT drug candidate
  • Relocation of VMIC lab to the National Biotechnology Research Park (NBRP), Nangang
2018
  • Completion of Phase I clinical trial of DBPR112 in Taiwan
2017
  • Initiation of Phase II clinical trial of DBPR108
  • Initiation of repeat-dose Phase I clinical trial of DBPR112 in Taiwan
  • IND approvals of DBPR114 by US FDA and TFDA
  • IND approval of DBPR211 by TFDA
  • Identification of DBPR117 the 1st biologics anti-RSPO3 mAb as an anti-cancer drug candidate
  • Establishment of VMIC contingent lab at NHRI Zhunan campus
2016
  • Identification of DBPR116 an opioid receptor modulator as a pain control drug candidate
  • Identification of DBPR216 a c-KIT inhibitor as an anti-cancer drug candidate
  • IND approvals of DBPR112 by US FDA and TFDA
  • IND approval of DBPR211 by US FDA
  • Technology transfer of DBPR115 to Taivex Therapeutics Co.
  • Establishment of The Platforms of Technology Service
2015
  • IND approval of  DBPR108 by CFDA and initiation of Phase I clinical trial
  • IND approvals of Phase II clinical trials of DBPR104 by US FDA and TFDA and initiation of Phase II clinical trial in Taiwan
  • IND approval of DBPR110 by US FDA
  • Identification of DBPR115 a PS-targeting drug conjugate as an anti-cancer drug candidate
  • Identification of DBPR215 a CXCR4 antagonist as a PBSCT drug candidate
2014
  • Identification of DBPR114 a multi-kinases inhibitor as an anti-cancer drug candidate
  • IND approval of DBPR108 by TFDA and initiation of a Phase I clinical trial of repeated doses of DBPR108 in Taiwan
2013
  • Technology transfer of DBPR110 to MICROBIO Co.
2012
  • IND approvals of DBPR108 by US FDA and TFDA and initiation of a Phase I clinical trial of single dose DBPR108 in Taiwan
  • Identification of DBPR112 an EGFR inhibitor as an anti-cancer drug candidate
  • Technology transfer of DBPR108 to Genovate Biotechnology Co. and the P-Team
  • Starting to join the Technology Development Program (TDP) for Nonprofit Research Organization funded by Ministry of Economic Affairs (MOEA)
2011
  • Identification of DBPR211 a peripheral CB1 receptor antagonist as an anti-diabetes drug candidate
  • Initiation of Phase I clinical trial of DBPR104 in Taiwan
2010
  • IND approvals of DBPR104 by US FDA and TFDA
  • Reorganized in to Institute of Biotechnology and Pharmaceutical Research in August
  • Identification of DBPR110 a NS5A inhibitor as an anti-HCV drug candidate
2009
  • Approval of DBPR108 by the Center for Drug Evaluation as Critical Path Program Index Case of 2009
  • Establishment of Pharmaceutical Development Lab in IBPR
  • Initiation of program “Pre-clinical and Clinical Development of Novel Anti-diabetic Drug Candidate, DBPR108
2008
  • 2008 International Symposium on Influenza Virus
  • Approvals of DBPR104 & DBPR204 by the Center for Drug Evaluation as Critical Path Program Index Cases of 2008
  • Identification of DBPR108 a inhibitor as an anti-diabetes drug candidate
  • “Pre-clinical and Clinical Development of Novel Anti-Diabetic Drug Candidate, DBPR108” program granted as the Case of Promoting Successful Biotech Investment by the Executive Yuan, Republic of China (Taiwan)
  • Technology Transfer of DBPR104 & DBPR204 to SynCore Biotechnology Co., Ltd (a new company and subsidiary of  the Sinphar Group)
  • Collaboration with Genovate Biotechnology Co. and Genelabs Technologies Inc. on HCV drug discovery
2007
  • 2007 International Symposium on the Influenza Virus
  • Initiation of new target-based cancer drug discovery projects
  • Approvals of DBPR104 & DBPR204 by the Center for Drug Evaluation as Critical Path Program Index Cases of 2007
2006
  • Initiation of Discovery and development of Anti-obesity Drugs of Central CB1 Antagonists (an industry-research collaborative project)
  • Initiation of Anti-influenza Drug Discovery Program (teamed up with Chang Gung University, National Tsing Hua University and Academia Sinica)
2005
  • 1st technology transfer project (DBPR303, sodium stibogluconate)
  • Completed of “Synthetic Rehearsal of Manufacturing Process of Tamiflu”
2004
  • 1st ROC patent granted (anti-enterovirus compound; TWI203254)
  • Identification of DBPR104 & DBPR204 vascular disrupting agents as anti-cancer drug candidates
  • Labs relocation to NHRI Zhunan campus
2003
  • Joined Anti-SARS Drug Development Program
  • Identification of DBPR103 & DBPR203 as anti-EV71 drug candidates
  • Identification of DBPR303 as anti-HCV drug candidate
  • 1st US patent granted (anti-enterovirus compound;US6,706,739B2)
2002
  • Labs relocation to National Defense Medical Center
  • 1st US patent application (anti-enterovirus compound)
  • 1st ROC patent application (anti-enterovirus compound)
1999
  • Establishment of animal pharmacology and pharmacokinetics labs
1998
  • Division of Biotechnology and Pharmaceutical Research was founded in January 1998
  • Establishment of high throughput screening Lab
  • Establishment of chemistry lab
Directors
2020 ~ present Jang-Yang Chang 張俊彥
2020 ~ 2020 Ming-Shiu Hung 洪明秀(Acting Director)
2017 ~ 2020 Chiung-Tong Chen 陳炯東
2014 ~ 2017 Chuan Shih 石全
2013~2014 Chung-Ming Chang 張仲明 (Acting Director)
2002 ~ 2013 Yu-Sheng Chao 趙宇生
2001~2001 Chung-Ming Chang 張仲明 (Acting Director)
1998 ~ 2000 Ming-Chu Hsu 許明珠
Share Button

Comments are closed.